These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37391955)

  • 21. [Drug treatment of chronic obstructive pulmonary disease on two levels of patient care: degree of compliance with recommended protocols].
    de Miguel Díez J; Izquierdo Alonso JL; Rodríguez González-Moro JM; de Lucas Ramos P; Molina París J
    Arch Bronconeumol; 2003 May; 39(5):195-202. PubMed ID: 12749801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD.
    Brophy C; Kastelik J; Gardiner E; Greenstone M
    Chron Respir Dis; 2008; 5(1):13-8. PubMed ID: 18303097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asthma and COPD medicines prescription-claims: A time-series analysis of England's national prescriptions during the COVID-19 pandemic (Jan 2019 to Oct 2020).
    Barrett R; Barrett R
    Expert Rev Respir Med; 2021 Dec; 15(12):1605-1612. PubMed ID: 34555287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
    Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of salbutamol and ipratropium bromide on arterial blood gases in patients with stable COPD].
    Ozdemir T; Geçkin E; Oğüş C; Cilli A
    Tuberk Toraks; 2003; 51(2):132-7. PubMed ID: 15143418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription practices for chronic obstructive pulmonary disease: findings from the national ambulatory medical care survey 1999-2010.
    Ford ES; Mannino DM; Giles WH; Wheaton AG; Liu Y; Croft JB
    COPD; 2014 Jun; 11(3):247-55. PubMed ID: 24568285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aclidinium bromide for stable chronic obstructive pulmonary disease.
    Ni H; Soe Z; Moe S
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD.
    De Backer LA; Vos WG; Salgado R; De Backer JW; Devolder A; Verhulst SL; Claes R; Germonpré PR; De Backer WA
    Int J Chron Obstruct Pulmon Dis; 2011; 6():637-46. PubMed ID: 22162649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
    Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
    J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
    Liao PA; Pan SW; Chen CY; Deng CY; Dong YH
    Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD.
    Oga T; Nishimura K; Tsukino M; Sato S; Hajiro T; Mishima M
    Chest; 2003 Jun; 123(6):1810-6. PubMed ID: 12796154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
    Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease.
    Arfè A; Nicotra F; Cerveri I; de Marco R; Vaghi A; Merlino L; Corrao G
    COPD; 2016 Oct; 13(5):540-6. PubMed ID: 26934569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
    Baloira Villar A; Vilariño Pombo C
    Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
    Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF
    Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y; Keeney E; Ghatehorde N; Dias S
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
    Appleton S; Jones T; Poole P; Pilotto L; Adams R; Lasserson TJ; Smith B; Muhammad J
    Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006101. PubMed ID: 16856113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.